The Ophthalmic Drugs Market Is Estimated To Witness High Growth Owing To Increasing Prevalence Of Eye Diseases
The ophthalmic drugs market is estimated to be valued at US$ 48.19 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The ophthalmic drugs market comprises drugs used in the treatment of various eye diseases and disorders. The major products include anti-glaucoma drugs, dry eye drugs, retinal disorders drugs, allergic conjunctivitis and inflammation drugs, anti-infective drugs, and other drugs. Anti-glaucoma drugs account for the largest share in the market due to the increasing prevalence of glaucoma.
Market Dynamics:
The growth of the ophthalmic drugs market is attributed to rising incidence of eye diseases. According to the estimates by WHO, there were around 2.2 billion cases of vision impairment or blindness globally in 2020. Of these, at least 1 billion cases of vision impairment may have been avoidable. The rapid increase in geriatric population is also driving market growth. According to United Nations, the global population aged 60 years and older is projected to double from 12% to 22% between 2015 and 2050. Older population has higher risks of developing various eye diseases. In addition, technological advancements in drug delivery devices such as progressive development of dry eye prescription devices and over-the-counter drops are expected to augment the market growth during the forecast period.
SWOT Analysis
Strength: The ophthalmic drugs market has strong research and development which leads to continual introduction of innovative drugs. Many companies are investing heavily in R&D to develop new products. The increasing prevalence of eye diseases like cataract, glaucoma etc. ensures growing demand for ophthalmic drugs. The market enjoys strong distribution channel as most major pharmaceutical companies have a large sales network globally.
Weakness: High costs associated with drug development and clinical trials put pressure on pricing of final products. The stringent regulatory approvals and legal compliance procedures prolong product launch timelines.
Opportunity: Rising geriatric population worldwide is increasing the patient pool for eye diseases. Emerging economies provide huge untapped market potential due to growing healthcare expenditure.
Threats: Entry of generic drugs after patent expiration of blockbuster brands affects revenues of innovator companies. Regulatory changes like price controls can impact profitability of market players.
Key Takeaways:
The Global Ophthalmic Drugs Market Size is expected to witness high growth, exhibiting CAGR of 5.6% over the forecast period, due to increasing prevalence of eye disorders. The global market size is estimated to reach US$ 48.19 Bn in 2023. Rapid urbanization, aging population and lifestyle changes have contributed to higher rates of diabetes, hypertension and obesity which are leading risk factors for diabetic retinopathy and other vision impairing disorders.
Regional analysis: North America dominated the global market in 2022, accounting for around 35% of global revenue, owing to sophisticated healthcare infrastructure and availability of advanced treatment options in the region. Asia Pacific is expected to be the fastest growing market during the forecast period, rising at a CAGR of over 6.5% due to large patient population, increasing healthcare expenditure and presence of emerging economies in the region offering market expansion opportunities.
Key players: Key players operating in the ophthalmic drugs market are Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG, Pfizer Inc., Bausch & Lomb Incorporated, F. Hoffmann-LA Roche Ltd. (Genentech, Inc.), among others. Major companies are focusing on new product approvals and geographical expansion into high growth markets through strategic collaborations.